Topical compositions incorporating silica fibers

ABSTRACT

Embodiments of the invention include topical compositions comprising silica fiber powder or dust and a topical carrier, for treatment of skin tissue. The silica fiber powder or dust may be generated from silica fiber mats that may be formed via electrospinning of a sol gel produced with a silicon alkoxide reagent, such as tetraethyl ortho silicate, alcohol solvent, and an acid catalyst.

RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applicationSer. No. 16/131,531, filed Sep. 14, 2018, which is acontinuation-in-part of U.S. patent application Ser. No. 15/934,599,filed Mar. 23, 2018, which claims the benefit of and priority to U.S.Provisional Patent Application No. 62/710,305, filed Feb. 16, 2018, andU.S. Provisional Patent Application No. 62/643,946, filed Mar. 16, 2018,the entire disclosure of each of which is hereby incorporated herein byreference. This application claims the benefit of and priority to U.S.Provisional Patent Application No. 62/729,085, filed Sep. 10, 2018, andU.S. Provisional Patent Application No. 62/651,386, filed Apr. 2, 2018,the entire disclosure of each of which is hereby incorporated herein byreference.

TECHNICAL FIELD

In various embodiments, the present invention relates to topicalcompositions incorporating silica fibers as an additive.

BACKGROUND

Collagen is a protein that provides the matrix that sustains the body'sstructures. It provides integrity, firmness and elasticity to tissues.Loss of collagen results in the wrinkles, lines, and loss of smoothnessassociated with aging skin. Since collagen is not significantly absorbedthrough the skin, nutritional supplements are sometimes used to boostcollagen levels, even though collagen is also poorly absorbed as adietary supplement.

Topical products that improve the integrity of skin, including aging ordamaged skin, are of great need.

SUMMARY

In accordance with various embodiments, the present invention providestopical compositions that comprise a silica fiber powder or dust (e.g.,a collection of fibrous fragments) and a topical carrier. Embodiments ofthe invention further provide methods for treating aging or damaged skinof a subject. In various embodiments, the methods involve application ofthe compositions to improve skin healing, to prevent or reduce scarring,reduce signs of aging, and/or to reduce pain and/or irritationassociated with damaged or diseased skin.

In various embodiments, the topical composition when applied to skinallows silica fiber dust to be deposited in macroscopic or microscopicbreaks in skin. The fiber dust or flakes may act as a collagen mimeticthat is not substantially biodegradable, and which may promote cellinfiltration and/or collagen deposition, and in some embodiments reduceslocal production of pain and inflammatory mediators. The topical carriermay be in the form of a lotion, ointment, paste, cream, foam, balm,soap, shampoo, or gel, and may include other active agents.

In accordance with various embodiments, the fiber composition isprepared by electrospinning a sol-gel into a silica fiber composition,followed by processing the fiber into a fine powder or dust, andincorporating the powder or dust with the topical carrier. In someembodiments, the silica fiber composition is electrospun from agelatinous material into a lightweight fiber mat. For example, thecomposition may be prepared by electrospinning a sol-gel, which may beprepared with a silicon alkoxide reagent, such as tetraethyl orthosilicate (TEOS), alcohol solvent, and an acid catalyst. In variousembodiments, the sol-gel is produced via ripening of sol undercontrolled environmental conditions, and/or the properties of the sol orsol-gel during the ripening process are monitored, in order to identifyvarious processing windows during which the electrospinning of thesol-gel may be successfully performed. As known in the art, a “sol” is acolloidal solution that gradually evolves towards the formation of a“gel,” i.e., a diphasic system containing both a liquid phase and solidphase. Herein, the term “sol-gel” is used to refer to the gel producedfrom the sol-gel process that may be electrospun into fibers or afibrous mat.

Known processes for electrospinning silica fibers do not yield a fibercomposition with sufficient flexibility and texture suitable or idealfor many applications. By slowly ripening the sol-gel under controlledenvironmental conditions, and/or monitoring the sol-gel during theripening process, the relatively short window to successfullyelectrospin the sol-gel may be identified and increased in duration. Inaccordance with embodiments of the invention, the composition isnon-rigid and has a soft texture similar to that of cotton. In someembodiments, the sol-gel is electrospun after a ripening process of atleast 2 days, or at least 3 days (e.g., from 2 to 7 days), under thecontrolled environmental conditions. The weight of the sol-gel and/oremission of ethylene vapors can be used as an indicator of when thesol-gel is at or near the ideal time to electrospin.

In various embodiments, the controlled environment for ripening (or“transitioning”) the sol may involve controlled conditions in terms ofhumidity, temperature, and optionally barometric pressure. For example,the humidity may be controlled within the range of about 30% to about90% or from about 40% to about 80%, and the temperature may becontrolled within the range of from about 50° F. to about 90° F. Bycontrolling the environmental conditions during ripening, the gel may beelectrospun during the time when spinning is optimal, which can occur ina very small window of only several minutes if the ripening process isaccelerated by direct heat. When ripening the sol at a constant humidityin the range of about 50% to 70% or 80% and a temperature of about 60 to80° F., the sol will ripen (gelatinize) in a few days, and the windowfor successful electrospinning may be expanded to at least severalhours, and in some embodiments several days. The sol may therefore beripened in an enclosure which may include one or more environmentalmonitors, such as a temperature reading device and/or a humidity readingdevice. Further, gases produced or released by the sol during theripening process and/or relative weight of the sol may be monitored todetermine a suitable or optimal time for electrospinning.

Once the sol is adequately ripened into a sol-gel, it is electrospun toform a mat of entangled silica fibers. Once electrospun, the silicafibers may have a variable diameter, such as in the range of from about50 nm to 5 μm. In some embodiments, the fibers are predominately in therange of about 100 nm to about 2 or predominately in the range of about200 to about 1000 nm. After the silica-fiber mat is successfully formed,it is, in various embodiments, divided into small fibrous fragments thatare utilized as an additive in any of a variety of different topicalcompositions. For example, the electrospun mat may be “fragmented,”i.e., fractured, cut, ground, milled, or otherwise divided into smallfragments that maintain a fibrous structure. As used herein, the term“fibrous fragments” (or “fibrous-mat fragments,” or simply “fragments”)refers to small particles, parts, or flakes of a fibrous mat having anaverage dimension larger (e.g., 5×, 10×, or even 100×) than the width ofat least some of the fibers of the mat. In various embodiments, theaverage size of a fibrous fragment is in the range of approximately 20μm to approximately 200 μm. Fibrous fragments may thus resemblemicroscopic-scale versions of the electrospun mat itself, e.g.,intertwined collections of silica fibers, and thus typically are porousand have low densities. Thus, fibrous fragments may be contrasted withother types of micro-scale particles, such as the substantiallyspherical particles used in colloidal silica, which are each unitary,individual units or grains, rather than small collections of fibers.Various portions of a fibrous fragment (e.g., the edges) may have sharpand/or broken edges resulting from the fracturing process utilized toform the fragments from the electrospun mat. As utilized herein, theterm “fiber dust” includes collections of particles generated via thefragmentation of electrospun fiber mats and/or fibers, and may includefibrous fragments and/or other powder particles resulting from suchfragmentation.

Embodiments of the present invention may employ silica fibers, fragmentsthereof, and/or compositions incorporating such fibers or fragments,and/or methods for fabricating such fibers or fragments detailed in U.S.patent application Ser. No. 15/934,599, filed on Mar. 23, 2018 (issuedas U.S. Pat. No. 10,111,783), and U.S. patent application Ser. No.16/131,531, filed on Sep. 14, 2018, the entire disclosure of each ofwhich is incorporated by reference herein.

The fiber dust or fibrous fragments are incorporated with a topicalcarrier. The topical composition may be a skin care composition or acosmetic composition. In some embodiments, the fiber dust or fragmentsare distributed in a carrier system such as water or any aqueoussolution containing organic or inorganic materials. The compositions maycontain one or more ingredients to modify or enhance their texture,appearance, scent performance or stability. Illustrative additives tothe compositions include: oily components, fatty components, ointmentbases, hydrophilic solvents, lipophilic solvents, emollients, water,buffering agents, pH-adjusting agents, preservatives, humectants,chelating agents, antioxidants, stabilizers, emulsifying agents,suspending agents, gel-forming agents, perfumes and fragrances, skinprotective agents, and antiseptics.

In some embodiments, the composition further comprises one or moreanti-inflammatory agents such as steroidal anti-inflammatory agents ornon-steroidal anti-inflammatory agents (NSAIDs). In some embodiments,the composition further comprises one or more antimicrobial agents. Insome embodiments, the composition further comprises one or more painreducing agents.

In various embodiments, the invention provides a method for treatingskin tissue in a subject, which comprises applying the topicalcomposition to skin tissue. The composition can be used routinely orperiodically. In some embodiments, the composition is applied at leastabout daily. In various embodiments, the method improves healing of theskin tissue and/or prevents or reduces tissue scarring, looseness ofskin, age spots, pain, and/or irritation.

Application of the composition can provide for improved or acceleratedhealing of damaged skin. For example, when the topical composition isapplied to skin that has cracks, small scrapes, blemishes, etc., thescaffolding is left behind in the small “wound” for cells to grow into.This speeds up the healing process and helps to reduce scarring. In someembodiments, the composition is applied to cracked skin, which canimprove tolerance of the skin to the environment, such as sun, wind, andcold.

In some embodiments, the composition is applied to a skin lesion,superficial wound or infection, acne, burn, ulcer, cut, scrape, rash,blister, allergic reaction, hives, or insect or spider bites or stings.Exemplary conditions include aging skin, dry skin, eczema, pruritus, sunburn, reaction to poison ivy or poison oak, post-surgery wound, skingraft, mosquito bites, and genetic diseases that impact skin integrity(such as but not limited to epidermolysis bullosa and ichthyosis). Insome embodiments, the composition is applied to diseased skin, which canbe a manifestation of a proliferative disorder (e.g., carcinoma orpre-carcinoma, such as a melanoma lesion, or psoriasis), or in someembodiments an autoimmune or inflammatory disorder, such as rosacea,acne, cutaneous manifestation of lupus, or dermatitis herpetiformis. Insome embodiments, the composition is applied to a microbial infection ofthe skin. In some embodiments, the composition is applied to skinaffected by shingles, providing, for example, relief from associatedpain. Other conditions that may benefit from the pain reducingproperties of the invention include neuropathy, joint pain, and gout.

In an aspect, embodiments of the invention feature a topical compositioncomprising, consisting essentially of, or consisting of a silica fiberpowder or dust, and a topical carrier.

Embodiments of the invention may include one or more of the following inany of a variety of combinations. The topical carrier may be a lotion,ointment, balm, paste, cream, foam, soap, shampoo, bath salt, and/orgel. The composition may further include one or more pharmaceutical orantimicrobial agents. The composition may further include an antibioticand/or antiseptic. The composition may further include ananti-inflammatory agent, immunosuppressant, and/or pain-reducing agent.The composition may further include an anti-fibrotic and/oranti-scarring agent.

The composition may be prepared by electrospinning a sol-gel into asilica fiber composition, processing the silica fiber composition intopowder or dust, and incorporating the powder or dust with the topicalcarrier. The sol-gel may be prepared with tetraethyl orthosilicate(TEOS). Prior to electrospinning the sol-gel, the sol-gel may beproduced from an initial sol comprising, consisting essentially of, orconsisting of 70% to 90% TEOS by weight, 8% to 25% ethanol by weight, anacid catalyst, and water. The initial sol may comprise, consistessentially of, or consist of 70% to 90% TEOS by weight, 8% to 25%ethanol by weight, an acid catalyst, and water. The initial sol maycontain 70% to 90% TEOS by weight, 8% to 25% ethanol by weight, an acidcatalyst, and the balance water. The initial sol may comprise, consistessentially of, or consist of 70% to 90% TEOS by weight, 8% to 25%ethanol by weight, an acid catalyst, and water. The initial sol maycontain 70% to 90% TEOS by weight, 8% to 25% ethanol by weight, an acidcatalyst, and the balance water. The initial sol may comprise, consistessentially of, or consist of 70% to 90% TEOS by weight, 8% to 25%ethanol by weight, an acid catalyst, and water. The initial sol maycomprise, consist essentially of, or consist of 70% to 90% TEOS byweight, 8% to 25% ethanol by weight, 1% to 10% water by weight, and theacid catalyst. The initial sol may comprise, consist essentially of, orconsist of 75% to 85% by weight TEOS, 12% to 20% by weight ethanol, andabout 2% to 5% by weight water. The initial sol may comprise, consistessentially of, or consist of about 80% by weight TEOS, about 17% byweight ethanol, and about 3% by weight water. The acid catalyst maycomprise, consist essentially of, or consist of HCl. The initial sol maycontain less than about 0.1% of the acid catalyst by weight. The initialsol may contain from 0.02% to 0.08% of the acid catalyst by weight. Theinitial sol may contain one or more reagents that alter one or moreproperties of the initial sol, the sol-gel, and/or the silica fibers.

Producing the sol-gel may include transitioning the initial sol for atleast 2 days under conditions where humidity is within the range ofabout 40% to about 80%, and the temperature is within the range of 50°F. to 90° F. The initial sol may be allowed to transition for at least 3days, at least 4 days, at least 5 days, at least 6 days, or at least 7days. The initial sol may be allowed to transition for 2 days to 10days, and for 2 days to 7 days in some embodiments. The sol-gel may beelectrospun when the weight is at from 20% to 40% of the starting weightof the initial sol or sol-gel before ripening (transitioning). Thesol-gel may be electrospun when the production of ethylene vapor is 10%to 20% relative to the peak production of ethylene vapors duringripening (transitioning) of the initial sol or sol-gel before ripening.The sol-gel may be electrospun when the production of ethylene vaportherefrom is 10% to 40% relative to the initial sol or sol-gel beforeripening (transitioning). The powder or dust may comprise, consistessentially of, or consist of particles and/or fibrous fragments thatmay have an average size (e.g., average diameter, length, width, orother dimension) ranging from approximately 20 μm to approximately 200μm. The fibers may have a variable diameter of from about 50 nm to about5 μm. The fibers may have a variable diameter of from about 200 nm toabout 1000 nm. The silica fiber powder or dust may consist essentiallyof or consist of SiO₂.

In another aspect, embodiments of the invention feature a method fortreating skin tissue in a subject. The method may comprise, consistessentially of, or consist of applying a topical composition to saidskin tissue. The topical composition comprises, consists essentially of,or consists of a silica fiber powder or dust, and a topical carrier. Thetopical composition may comprise, consist essentially of, or consist ofany topical composition described herein.

Embodiments of the invention may include one or more of the following inany of a variety of combinations. The method may improve healing of theskin tissue and/or prevent or reduce tissue scarring, pain, and/orirritation. The subject may be a mammal. The subject may be a veterinarypatient, such as a dog, cat, or horse. The subject may be a humanpatient. The composition may be applied to a skin lesion, scar,superficial wound or infection, burn, cut, scrape, rash, blister, bugbite, poison ivy or poison oak, and/or hives. The subject may have agenetic disease of the skin, e.g., epidermolysis bullosa or ichthyosis.The subject may have a first, second, or third degree burn, orcombination thereof. The composition may be applied to a sun burn. Thecomposition may be applied to a melanoma lesion. The composition may beapplied to aging skin, age spots, dry skin, cracked skin, and/or scartissue. The composition may be applied to skin affected by eczema and/oratopic dermatitis. The composition may be applied to skin affected bypsoriasis. The composition may be applied to skin affected by acneand/or rosacea. The composition may be applied to a post-surgery woundand/or sutures (e.g., sutures utilized to at least partially close awound). The composition may be applied to skin affected by pruritus. Thecomposition may be applied to skin affected by shingles and/or lupus.The subject may be affected by neuropathy, joint pain, and/or gout. Thecomposition may be applied to skin impacted by dermatitis herpetiformisand/or dermatomyositis. The composition may be applied to skin showingsigns of microbial infection and/or skin infected by one or moremicrobes, such as a virus, bacteria, or fungus. The microbial infectionmay be HPV, herpes simplex virus, varicella-zoster virus, fungalinfection, and/or Staphylococcus infection. The composition may beapplied as a bath including the silica fiber powder or dust (e.g., thetopical carrier may include, consist essentially of, or consist of waterand/or another bathing fluid).

These and other objects, along with advantages and features of thepresent invention herein disclosed, will become more apparent throughreference to the following description, the accompanying drawings, andthe claims. Furthermore, it is to be understood that the features of thevarious embodiments described herein are not mutually exclusive and mayexist in various combinations and permutations. As used herein, theterms “approximately,” “about,” and “substantially” mean±10%. The term“consists essentially of” means excluding other materials thatcontribute to function, unless otherwise defined herein. Nonetheless,such other materials may be present, collectively or individually, intrace amounts.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, like reference characters generally refer to the sameparts throughout the different views. Also, the drawings are notnecessarily to scale, emphasis instead generally being placed uponillustrating the principles of the invention. In the followingdescription, various embodiments of the present invention are describedwith reference to the following drawings, in which:

FIGS. 1A-1D are scanning electron microscopy (SEM) images of fibers spunin accordance with embodiments of the invention. Images in FIGS. 1A-1Dare at, respectively, 50, 100, 200, and 500 micron scale. As shown, thefibers are flexible, smooth, dense, and continuous (not fractured).

FIG. 2 shows an SEM image (20 micron scale is shown) of fibers spun at anon-optimal time. The fibers are rigid, with fractures clearly evident.

FIG. 3 shows a fiber mat spun with a thickness of about ¼ inch inaccordance with embodiments of the invention. The mat has a soft,flexible texture.

FIGS. 4A and 4B compare a silica fiber mat that was electrospun when thesol-gel was transitioned in accordance with certain embodiments of theinvention (FIG. 4A), with a fiber mat that was spun early, before thesol-gel was optimally ripened (FIG. 4B).

FIGS. 5A and 5B show SEM images of fiber dust in accordance withembodiments of the invention, with 100 μm scale shown.

FIGS. 6A and 6B show a shingles rash prior to treatment with a silicafiber topical composition in accordance with embodiments of theinvention (FIG. 6A) and the rash after of about 1.5 days with frequentapplication in accordance with embodiments of the invention (FIG. 6B).

FIG. 7A shows a burn prior to treatment with a silica fiber topicalcomposition in accordance with embodiments of the invention.

FIG. 7B shows the burn of FIG. 7A after of about 4 days of frequentapplication with a silica fiber topical composition in accordance withembodiments of the invention.

DETAILED DESCRIPTION

Embodiments of the present invention provide topical compositions thatcomprise a silica fiber powder or dust, and a topical carrier. In otheraspects, the invention provides methods for treating aging or damagedskin of a subject. In various embodiments, the methods involveapplication of the compositions to improve skin healing, to prevent orreduce scarring, reduce signs of aging, or to reduce pain or irritationassociated with damaged skin. In some embodiments, the compositionsimprove the look and appearance of skin.

In various embodiments, the topical composition when applied to skinallows silica fiber dust to be deposited in macroscopic or microscopicbreaks in skin. The fiber dust or flakes act as a collagen mimetic thatis not substantially biodegradable, and which may promote cellinfiltration and/or collagen deposition, and in some embodiments reduceslocal production of pain and/or inflammatory mediators.

In various embodiments, the fiber dust is incorporated with a topicalcarrier, which may be in the form of a lotion, ointment, balm, paste,cream, foam, soap, shampoo, or gel, and may comprise other activeagents.

The fiber composition is prepared by electrospinning a sol-gel into asilica fiber composition, followed by processing the fiber into a finepowder or dust, and incorporating the powder or dust with the topicalcarrier.

In some embodiments, the silica fiber composition is electrospun from agelatinous material into a lightweight fiber mat. For example, thecomposition may be prepared by electrospinning a sol-gel, which can beprepared with a silicon alkoxide reagent, such as tetraethyl orthosilicate (TEOS), alcohol solvent, and an acid catalyst.

Known processes for electrospinning silica fibers do not yield a fibercomposition with sufficient flexibility and texture suitable or idealfor topical compositions. Instead, these structures are comparativelybrittle, rigid, and compact; and fiber mats are thin and will easilyfracture. Generally, these materials lack the physical characteristicsto mimic collagen deposition. In various embodiments, to achieve asuperior material for tissue repair, it is important to electrospin thesol-gel once it is appropriately ripened, to achieve a composition withthe desired physical characteristics. By slowly ripening the sol-gelunder controlled environmental conditions, and/or monitoring the sol-gelduring the ripening process, the relatively short window to successfullyelectrospin the sol-gel can be identified and increased in duration. Inaccordance with embodiments of the invention, the composition isnon-rigid and has a soft texture similar to that of cotton.

In accordance with embodiments of the invention, the silica fibercomposition, when applied to wounded tissue, acts as a non-biodegradablescaffold that supports tissue healing, regeneration, and/or integrity.The composition acts as a collagen biomimetic at the site of damagedtissue, providing an environment conducive for regeneration and growthof dermal cells and/or natural deposition of collagen. Without wishingto be bound by theory, the composition and methods described hereinlimit pain and inflammation at the site of damaged tissue. Further,uncontrolled tissue degradation processes can destroy newly depositedcollagen. The composition of the invention provides a non-biodegradablescaffold that is not destroyed by proteases released at the site oftissue injury, but provides an optimal environment for population andgrowth of dermal cells. The fibers will become an integral part of theregenerating tissue.

The fibers may have a variable or more uniform diameter, such as in therange of from about 50 nm to 5 μm. In some embodiments, the fibers arepredominately in the range of about 100 nm to about 2 μm, orpredominately in the range of about 200 to about 1000 nm. The size(s) ofthe fibers is a better mimic for natural collagen, compared to, forexample, brittle scaffolding including those intended to have a moreuniform structure.

In some embodiments, the sol-gel for preparing the silica fibercomposition is prepared by a method that includes preparing a firstmixture containing an alcohol solvent, a silicon alkoxide reagent suchas tetraethylorthosilicate (TEOS); preparing a second mixture containingan alcohol solvent, water, and an acid catalyst; fully titrating thesecond mixture into the first mixture; and processing (ripening) thecombined mixture to form a gel for electrospinning. In some embodiments,the silicon alkoxide reagent is TEOS. Alternative silicon alkoxidereagents include those with the formula Si(OR)₄, where R is from 1 to 6,and preferably 1, 2, or 3.

In some embodiments, the sol comprises, consists essentially of, orconsists of about 70% to about 90% by weight silicon alkoxide (e.g.,TEOS), about 5% to about 25% by weight alcohol solvent (e.g., anhydrousethanol), an acid catalyst (e.g., less than about 0.1% by weight whenusing HCl) and water. Any sol or sol-gel described herein may includethe balance water (i.e., water may constitute any amount of the sol orsol-gel that is otherwise unspecified). Any sol or sol-gel describedherein may optionally contain one or more reagents that may or do alterone or more properties of the sol, the sol-gel, and/or the silicafibers. Such reagents may include, but are not limited to, for example,polymers and polymeric solutions, inert reagents, alcohols, organicand/or aqueous solvents, organic salts, inorganic salts, metals, metaloxides, metal nitrides, metal oxynitrides, carbon (e.g., graphene,graphite, fullerenes, etc.), etc.

In some embodiments, the sol contains 70% to 90% tetraethylorthosilicate (TEOS) by weight, 8% to 25% ethanol by weight, 1% to 10%water by weight, and an acid catalyst. In some embodiments, the solcontains 75% to 85% by weight TEOS, 12% to 20% by weight ethanol, andabout 2% to 5% by weight water. An exemplary sol contains about 80% byweight TEOS, about 17% by weight ethanol, and about 3% by weight water.In some embodiments, the acid catalyst is HCl. For example, the sol maycontain less than about 0.1% HCl by weight. For example, the sol maycontain from 0.02% to 0.08% HCl by weight. In various embodiments, thesol does not contain an organic polymer, or other substantial reagents,such that the fiber composition will be substantially pure SiO₂. Invarious embodiments, the sol does not include inorganic salts (e.g.,sodium chloride, lithium chloride, potassium chloride, magnesiumchloride, calcium chloride, and/or barium chloride), nor are, in variousembodiments, inorganic salts mixed with other components of the sol orinto the sol itself. In various embodiments, the fiber composition doesnot include metals or metal oxides (e.g., TiO₂ or ZrO₂). In variousembodiments, the fiber composition consists essentially of SiO₂, i.e.,contains only SiO₂ and unintentional impurities, and, in someembodiments, species and/or complexes resulting from the incompleteconversion of the sol to SiO₂ (e.g., water and/or chemical groups suchas ethoxy groups, silanol groups, hydroxyl groups, etc.).

In some embodiments, the alcohol solvent is an anhydrous denaturedethanol, or in some embodiments, methanol, propanol, butanol or anyother suitable alcohol solvent. The first mixture may be agitated, forexample, using a magnetic stirrer, vibration platform or table, or otheragitation means. The second mixture contains an alcohol solvent, water,and an acid catalyst. The alcohol solvent may be an anhydrous denaturedalcohol, or may be methanol, propanol, butanol or any other suitablyprovided alcohol solvent. Water may be distilled water or deionizedwater. Enough acid catalyst is added to the mixture to aid in thereaction. This acid catalyst may be hydrochloric acid, or may besulfuric acid or other suitable acid catalyst. The second mixture may beagitated, for example, magnetic stirrer, vibration platform or table, orother agitation means. In some embodiments, the first mixture (or sol)and the second mixture (or sol) are created without the use of directheat (i.e., heat applied via extrinsic means such as a hot plate orother heat source).

According to various embodiments, the first mixture and the secondmixture are combined by dripping or titrating the second mixture intothe first mixture, preferably with agitation. The combined mixture isthen further processed by allowing the sol to ripen in a controlledenvironment until a substantial portion of the alcohol solvent hasevaporated to create a sol-gel suitable for electrospinning. Forexample, the controlled environment may include an enclosure with atleast one vent and optionally a fan to draw gases away from the mixture,and which may involve controlled conditions in terms of humidity,temperature, and optionally barometric pressure. For example, thehumidity may be controlled (e.g., via use of conventional humidifiersand/or dehumidifiers) within the range of about 30% to about 90%, suchas from about 40% to about 80%, or in some embodiments, from about 50%to about 80%, or from about 50% to about 70% (e.g., about 55%, or about60%, or about 65%). Some humidity may be helpful to slow evaporation ofsolvent, and thereby lengthen the window for successful electrospinning.In some embodiments, the temperature is in the range of from about 50°F. to about 90° F., such as from about 60° F. to about 80° F., or fromabout 65° F. to about 75° F. In various embodiments, the sol is notexposed to heat over 150° F. or heat over 100° F., so as to avoidaccelerating the transition. In some embodiments, barometric pressure isoptionally controlled (e.g., using a low pressure vacuum source such asa pump or a fan). By controlling the environmental conditions duringripening, the time period during which the gel may be electrospun may belengthened; this time period may be a small window of only severalminutes if the ripening process is too accelerated, such as with directheat. When ripening the sol at a constant humidity of about 55% andtemperature of about 72° F., the sol will ripen (gelatinize) in a fewdays, and the window for successful electrospinning may be expanded toat least several hours, and in some embodiments several days. In variousembodiments, the ripening process takes at least 2 days, or at least 3days in some embodiments. However, in various embodiments the ripeningdoes not take more than 10 days, or more than 7 days. In someembodiments, the ripening process takes from 2 to 10 days, or from 2 to7 days, or from 2 to 5 days, or from 2 to 4 days (e.g., about 2, about3, or about 4 days). In various embodiments, the sol-gel is spinnablewell before it transitions into a more solidified, non-flowable mass.

The enclosure space for ripening the sol-gel may include a vent on atleast one surface for exhausting gases from within the enclosure, andoptionally the vent may include a fan for exhausting gases producedduring the ripening process. The enclosure space may optionally includea heating source (e.g., one or more heating elements, for exampleresistive heating elements) for providing a nominal amount of heatwithin the enclosure space, to maintain a preferred temperature. In someembodiments, a source of humidity (e.g., an open container of water orother aqueous, water-based liquid) is provided within the enclosureenvironment to adjust the humidity to a desired range or value. Theenclosure may further include one or more environmental monitors, suchas a temperature reading device (e.g., a thermometer, thermocouple, orother temperature sensor) and/or a humidity reading device (e.g., ahygrometer or other humidity sensor).

In some embodiments, the sol-gel is electrospun after a ripening processof at least 2 days, or at least 36 hours, or at least 3 days, or atleast 4 days, or at least 5 days at the controlled environmentalconditions (but in various embodiments, not more than 10 days or notmore than 7 days under the controlled environmental conditions). Byslowing the ripening process, the ideal time to spin the fibers can beidentified. The weight of the sol-gel may be used as an indicator ofwhen the sol-gel is at or near the ideal time to electrospin. Withoutintending to be bound by theory, it is believed that the viscosity ofthe sol-gel is a poor determinant for identifying the optimal time forelectrospinning. For example, in various embodiments, the sol-gel isfrom about 10% to about 60% of the original weight of the sol (based onloss of alcohol solvent during transitioning). In some embodiments, thesol-gel is from 15 to 50% of the original weight of the sol, or in therange of about 20 to about 40% of the original weight of the sol.

In some embodiments, the sol-gel is ripened for at least 2 days, or atleast 36 hours, or at least 3 days, or at least 4 days, or at least 5days, and is electrospun when the ethylene vapors produced by thecomposition are between about 10% and about 40% of the vapors producedby the starting sol, such as in the range of about 10% and about 25%, orin the range of about 10% to about 20%. Ethylene is a colorlessflammable gas with a faint sweet and musky odor (which is clearlyevident as solvent evaporation slows). Ethylene is produced by thereaction of ethanol and acid. Ethylene may optionally be monitored inthe vapors using a conventional ethylene monitor. In other embodiments,gases produced by the sol during the sol ripening process are monitoredto determine a suitable or optimal time for electrospinning. Gasprofiles may be monitored using gas chromatography.

In various embodiments, the sol-gel may be ripened for a shorter periodof time, as long as the sol-gel remains spinnable via electrospinning.The resulting silica fiber mat or collection of fibers may in some casesbe more brittle after ripening for a shorter time period, but suchbrittleness may not prevent the fragmenting of the fibers and dispersioninto various different topical compositions.

The processing of the sol-gel mixture may require stirring or otheragitation of the mixtures at various intervals or continuously due tothe development of silicone dioxide crystalline material on the topsurface of the mixtures. This development of crystalline material on thetop surface slows the processing time and it is believed that thecrystalline material seals off exposure of the mixture to the gaseousvacuum provided within the enclosure space. In some embodiments, anysolid crystalline material is removed from the mixture.

Upon completion of the sol-gel process, the sol-gel is then electrospunusing any known technique. The sol or sol-gel may be preserved (e.g.,frozen or refrigerated) if needed (and such time generally will notapply to the time for ripening). An exemplary process forelectrospinning the sol-gel is described in Choi, Sung-Seen, et al.,Silica nanofibers from electrospinning/sol-gel process, Journal ofMaterials Science Letters 22, 2003, 891-893, which is herebyincorporated by reference in its entirety. Exemplary processes forelectrospinning are further disclosed in U.S. Pat. No. 8,088,965, whichis hereby incorporated by reference in its entirety.

In an exemplary electrospinning technique, the sol-gel is placed intoone or more syringe pumps that are fluidly coupled to one or morespinnerets. The spinnerets are connected to a high-voltage (e.g., 5 kVto 50 kV) source and are external to and face toward a groundedcollector drum. The drum rotates during spinning, typically along anaxis of rotation approximately perpendicular to the spinning directionextending from the spinnerets to the drum. As the sol-gel is supplied tothe spinnerets from the syringe pumps (or other holding tank), the highvoltage between the spinnerets and the drum forms charged liquid jetsthat are deposited on the drum as small entangled fibers. As the drumrotates and electrospinning continues, a fibrous mat of silica fibers isformed around the circumference of the drum. In various embodiments, thespinnerets and syringe pump(s) may be disposed on a movable platformthat is movable parallel to the length of the drum. In this manner, thelength along the drum of the resulting fiber mat may be increasedwithout increasing the number of spinnerets. The diameter of the drummay also be increased to increase the areal size of the electrospun mat.The thickness of the mat may be largely dependent upon the amount ofsol-gel used for spinning and thus the amount of electrospinning time.For example, the mat may have a thickness of greater than about ⅛ inch,or greater than about ¼ inch, or greater than about ⅓ inch, or greaterthan about ½ inch.

After completion of the electrospinning process, the resulting mat isremoved from the drum. For example, the mat may be cut and peeled awayfrom the drum in one or more pieces. The mat may then be divided intosmall fibrous fragments that may be incorporated into the topicalcomposition. In various embodiments, the resulting fibrous fragments areeach intertwined collections of silica fibers, rather than unitary solidparticles. In some embodiments, the electrospun mat may be fractured,cut, ground, milled, or otherwise divided into small fragments thatmaintain a fibrous structure. In some embodiments, the mat (or one ormore portions thereof) is rubbed through one or more screens or sieves,and the mesh size of the screen determines, at least in part, the sizeof the resulting fibrous fragments or powder or dust produced from theelectrospun mat. For example, the mat or mat portions may be rubbedthrough a succession of two or more screens having decreasing mesh sizes(e.g., screens having mesh numbers of 100, 200, 300, or even 400), inorder to produce a powder or dust or collection of fibrous fragmentshaving the desired sizes.

The fiber dust or fibrous fragments are incorporated with a topicalcarrier, which can be in the form of a lotion, ointment, balm, paste,cream, foam, soap, shampoo, conditioner, or gel. The topical compositioncan be a skin care composition or a cosmetic composition. In someembodiments, the fiber dust or fragments are distributed in a carriersystem such as water or any aqueous solution containing organic orinorganic materials. The compositions may contain one or moreingredients to modify or enhance their texture, appearance, scentperformance or stability. Illustrative additives to the compositionsinclude: oily components, fatty components, ointment bases, hydrophilicsolvents, lipophilic solvents, emollients, water, buffering agents,pH-adjusting agents, preservatives, humectants, chelating agents,antioxidants, stabilizers, emulsifying agents, detergents, suspendingagents, gel-forming agents, perfumes and fragrances, skin protectiveagents, and antiseptics.

In various embodiments, the fiber dust or fibrous fragments areincorporated into the composition at from about 5 mg/ml to about 500mg/ml, or from about 5 mg/ml to about 400 mg/ml, or from about 5 mg/mlto about 250 mg/ml. In some embodiments, the dust or fiber fragments areincorporated into the composition at from about 10 mg/ml to about 200mg/ml, or from about 10 mg/ml to about 150 mg/ml, or from about 25 mg/mlto about 100 mg/ml.

The topical composition may comprise oily or fatty components, which areconstituents of the hydrophobic phase, and can include one or more of:almond oil, castor oil, cacao butter, coconut oil, corn oil, cottonseedoil, linseed oil, olive oil, palm oil, peanut oil, poppy seed oil,rapeseed oil, sesame oil, soybean oil, sunflower oil, teaseed oil,jojoba oil, mineral oils, silicone oils, fatty oils, liquid paraffin,beeswax, lanolin, white soft paraffin, yellow soft paraffin, petrolatum,triglycerides, cetyl alcohol, stearyl alcohol, isopropyl myristate,oleic acid, isopropyl palmitate, stearic acid, sorbitan esters of fattyacids, sorbitan esters of fatty acids and ethylene oxide (includingTween).

The topical composition may comprise an aqueous phase, which constitutesthe hydrophilic phase and which may comprise water, one or more otherhydrophilic solvents, and/or one or more surfactants and/or emulsifier.In various embodiments, the aqueous phase may comprise solvents such aswater, polyethylene glycol, propylene glycol, glycerol, sorbitol, andalcohols such as ethanol and isopropyl alcohol.

The composition may comprise one or more emulsifiers (emulsifyingagents), which can be part of the aqueous phase and/or oil phase. Theterm “emulsifier” means an amphiphilic molecule possessing both polarand non-polar regions which are covalently bound and capable of reducingthe surface tension of water and for the interfacial tension betweenwater and an immiscible liquid. Emulsifiers include soaps, detergents,surface active agents, and the like. The emulsifier can be cationic,anionic, non-ionic, or amphoteric. Exemplary emulsifiers includenon-ionic emulsifiers such as polyol esters (e.g. ethylene glycol,diethylene glycol, glycol stearate and propylene glycol monoesters offatty acids), and glycerol esters (e.g. glyceryl stearate, glycerylmonooleate, glycerylmonolaurate, glyceryl ricinolate, glycerylmonocaprylate). Exemplary emulsifiers further include Sorbitanderivatives, which are esters of cyclic anhydrides of sorbitol with afatty acid. These include sorbitan monolaurate, sorbitan monooleate,sorbitan monostearate, sorbitan monopalmitate, sorbitan sesquioleate,sorbitan trioleate, sorbitan tristearate, polyoxyethylene sorbitanesters (e.g. polyoxyethylene sorbitan monostearate, polyoxyethylenesorbitan tristearate, polyoxyethylene sorbitan monooleate). Exemplaryemulsifiers also include polyoxyethylene esters, which are mixtures ofmono- or di-fatty acids esters (from C12 to C18) of polyoxyethyleneglycol. These include stearate esters of PEG (PEG-40, PEG-50 andPEG-55), as well as laurate, oleate, and myristate esters of PEG.

The composition can comprise polymeric thickeners including gums such asacacia, alginates, carageenan, chitosan, collagen, tragacanth andxantham; celluloses, acrylic acids, colloidal solids such as silica,clays and microcrystalline cellulose, hydrogels such as polyvinylalcohol and polyvinylpyrrolidone, as well as thermoreversible polymerssuch as poloxamers.

The composition may further comprise one or more pharmaceutical orantimicrobial agents suitable for topical application. Exemplarypharmaceutical agents include anti-fibrotic and anti-scarring agents.

In some embodiments, the composition comprises an antibiotic orantiseptic. Antibiotics suitable for use in the present inventioninclude, but are not limited to, cephalosporin antibiotics, tetracyclineantibiotics, beta-lactams, carbapenem antibiotics, polymyxin B(neosporin), neomycin, and bacitracin. Antiseptics include, withoutlimitation, phenol, meta-cresol, methylparaben, and sodium benzoate.

In some embodiments, the composition further comprises one or moreanti-inflammatory agents such as steroidal anti-inflammatory agents ornon-steroidal anti-inflammatory agents (NSAIDs). Steroids, particularlythe adrenal corticosteroids and their synthetic analogues, are wellknown in the art. Examples of corticosteroids include, withoutlimitation, hydroxyltriamcinolone, alpha-methyl dexamethasone,beta-methyl betamethasone, beclomethasone dipropionate, clobetasolvalerate, desonide, desoxymethasone, dexamethasone, diflorasonediacetate, diflucortolone valerate, fluadrenolone, flucloroloneacetonide, flumethasone pivalate, fluosinolone acetonide, fluocinonide,flucortine butylester, fluocortolone, fluprednidene (fluprednylidene)acetate, flurandrenolone, halcinonide, triamcinolone acetonide,cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosonediacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide,betamethasone, chloroprednisone, clocortelone, clescinolone,dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone,fluperolone, fluprednisolone, hydrocortisone, paramethasone,prednisolone, methylprednisolone, prednisone, and budesonide. NSAIDSthat may be used in the composition, include salicylic acid, acetylsalicylic acid, methyl salicylate, glycol salicylate, salicylmides,benzyl-2,5-diacetoxybenzoic acid, ibuprofen, fulindac, naproxen,ketoprofen, etofenamate, phenylbutazone, and indomethacin. In someembodiments, the composition comprises at least one active agent forreducing pain, including but not limited to cortisone, hydrocortisone,acetaminophen, or a cannabinoid.

In various embodiments, the invention provides a method for treatingskin tissue in a subject. The method comprises applying the topicalcomposition described herein to skin tissue. The composition can beapplied routinely or periodically. In some embodiments, the compositionis applied at least about daily, and in some embodiments from 1 to about10 times per day. In various embodiments, the method improves healing ofthe skin tissue and/or prevents or reduces tissue scarring, looseness ofskin, signs of aging, pain, and/or irritation.

Application of the composition can provide for improved or acceleratedhealing of damaged skin. For example, when the topical composition isapplied to skin that has cracks, small scrapes, blemishes, etc., thescaffolding is left behind in the small “wound” for cells to grow into.This speeds up the healing process and helps to reduce scarring. In someembodiments, the composition in lotion or other form is applied to thecracked skin (e.g., on the face, mouth or lips, neck, hands, arms,shoulders, legs, scalp, fingers, etc.) to improve tolerance of the skinto the environment, such as sun, wind, and cold, thereby reducing theimpact of age and environment on the appearance, feel, and/or functionof the skin. In some embodiments, the composition is a lip balm, whichcan comprise the silica dust suspended in a wax base (e.g., carnaubawax, paraffin, and/or beeswax). Alternatively, the lip balm may be anointment, e.g., comprising petroleum jelly or similar base, includingbases described herein. In still other embodiments, the composition isapplied as a soap or shampoo during bathing. In some embodiments, thesilica composition is a bath salt employed for bathing.

In some embodiments, the composition is applied to an insect or spiderbite or sting, including bee sting, wasp sting, mosquito bite, spiderbite, flea bite, fly or ant bites, bits from bed bugs, or others. Insome embodiments, the composition is applied to skin that has beencontacted with or is manifesting a reaction to poison ivy or poison oak.In other embodiments, the composition is applied to a skin allergicreaction or hives. The composition in these embodiments may includeadditional agents to reduce itch or swelling (e.g., corticosteroid orantihistamine), pain (e.g., acetaminophen or NSAID), or allergicresponses (e.g., antihistamine). Exemplary antihistamines includebrompheniramine, carbinoxamine maleate, chlorpheniramine, clemastine,diphenhydramine, hydroxyzine triprolidine, cetirizine, desloratadine,fexofenadine, levocetirizine, loratadine, and oloptadine.

In some embodiments, the composition is applied to skin showing signs ofmicrobial infection, including HPV (e.g., wart), herpes simplex virus(e.g., cold sore), varicella-zoster virus (e.g., chicken pox orshingles), fungal infection (e.g., candidiasis or tinea versicolor), orStaphylococcus infection or over colonization. In some embodiments, thecomposition comprises one or more antibiotics (e.g., antibacterial oranti-fungal agent), antiviral agent, or antiseptic.

In some embodiments, the subject is a mammal. Subjects includeveterinary patients such as a dog, cat, or horse, among others. In someembodiments, the patient is a human patient. In some embodiments, thepatient is a pediatric patient.

In some embodiments, the composition is applied to a skin lesion,superficial wound or infection (e.g., acne), burn, cut, scrape, rash(e.g., diaper rash), blister (including ruptured blister), or hives. Insome embodiments, the composition is applied to cracked or scraped skin.In some embodiments, the composition is applied to aging skin or dryskin, including eczema, atopic dermatitis, or pruritus. In someembodiments, the topical composition normalizes the tissuemicroenvironment, and may reduce pain and inflammation at the site,and/or provide a microscaffold for dermal cells to multiply and growinto, and in some embodiments induce collagen deposition. In someembodiments, the subject has a first, second, or third degree burn, or acombination thereof. In some embodiments, the composition is applied toa sun burn, and reduces pain or discomfort. In some embodiments, thecomposition is applied to a post-surgery wound, including skin graft,skin comprising sutures, or cosmetic surgery wound.

For treatment of severe wounds and burns, it may first be necessary toapply portions of fiber mats directly to the wound for several days (seeU.S. Pat. No. 10,111,783, which is hereby incorporated by reference inits entirety). Once new skin is substantially formed over the wound orburn area, the subject transitions to application of the lotiondescribed herein. Lotion is general applied one or more time daily, andcan be used continuously until the skin barrier has normalized.

In some embodiments, the composition is applied to age spots (e.g.,solar lentigines). Applying the composition routinely (e.g., at leastdaily) for several days can fade or reduce visible age spots.

In some embodiments, because the fiber material substantially reducespain from the site of tissue damage, the patient may be able to forgotherapy with a pain medication such as an opioid.

In some embodiments, the subject has a genetic disease that impacts skinbarrier function, such as but not limited to epidermolysis bullosa orichthyosis.

Epidermolysis bullosa (EB) is a group of mainly inherited connectivetissue diseases that cause blisters in the skin and mucosal membranes.It is a result of a defect in anchoring between the epidermis anddermis, resulting in friction and skin fragility. EB often involvesformation of blisters following trivial trauma.

In some embodiments, the subject has epidermolysis bullosa simplex,which results in blisters at the site of rubbing, and typically affectsthe hands and feet. In some embodiments, the subject has junctionalepidermolysis bullosa, which affects laminin and collagen. Junctionalepidermolysis bullosa also presents with blisters at the site offriction, especially on the hands and feet. Dystrophic epidermolysisbullosa is an inherited variant affecting the skin and other organs, andinvolves skin that is very fragile. Dystrophic epidermolysis bullosa iscaused by genetic defects (or mutations) within the gene encoding theprotein type VII collagen (collagen VII).

The human skin consists of two layers: an outermost layer called theepidermis and a layer underneath called the dermis. In individuals withhealthy skin, there are protein anchors between these two layers thatprevent them from moving independently from one another (shearing). Inpeople born with EB, the two skin layers lack the protein anchors thathold them together, resulting in extremely fragile skin. Even minormechanical friction (like rubbing or pressure) or trauma will separatethe layers of the skin and form blisters and painful sores. Sufferers ofEB have compared the sores with third-degree burns.

In some embodiments, the subject has ichthyosis. Ichthyosis is a familyof genetic skin disorders characterized by dry, thickened, scaly skin.The more than 20 types of ichthyosis range in severity of symptoms,outward appearance, and underlying genetic cause. The severity ofsymptoms can vary, from the mildest, most common, types such asichthyosis vulgaris, which may be mistaken for normal dry skin, up tolife-threatening conditions such as harlequin-type ichthyosis. Invarious embodiments, the topical composition is applied to a subjecthaving any of the types of ichthyosis, including harlequin ichthyosis.

In some embodiments, the composition is applied to diseased skin, whichcan be a manifestation of a proliferative disorder (e.g., carcinoma,pre-carcinoma, or melanoma lesion, or other cancer lesion, orpsoriasis), or in some embodiments an autoimmune or inflammatorydisorder. For example, in some embodiments, the composition is appliedfor treatment of rosacea or acne. Autoimmune manifestations includecutaneous manifestation of lupus and dermatitis herpetiformis, ordermatomyositis. In some embodiments, the composition is applied to skinaffected by shingles, providing, for example, relief from associatedpain and reduction in associated rash. In some embodiments, includingbut not limited to subjects experiencing shingles, psoriasis, or eczema,the composition can be applied topically to affected areas of the skin,or alternatively, applied during bathing (using a soap, shampoo, or bathsalt composition comprising the silica dust).

Other conditions that benefit from the composition in some embodimentsinclude neuropathy, joint pain, and gout. In some embodiments, thecomposition is applied to the skin in the area of the pain (for example,to generally intact skin surrounding a painful joint).

In some embodiments, the composition is applied to the affected area atleast about daily for at least about 1 week, or at least about 2 weeks.In some embodiments, the composition is applied between once and tentimes per day, or in some embodiments, from once to about four times perday, or from one to three times daily. In some embodiments, the regimenis continued for at least one week, or at least two weeks, or at leastone month, or at least two months, or at least four months, or at leastsix months, or more. In some embodiments, the regimen is continued forsix months or more. For subjects having a genetic disease of the skin,the regimen may be continuous.

Embodiments of the invention will now be described with respect to thefollowing examples.

EXAMPLES Example 1: Preparation of Silica Fiber Mat

Silica fibers were prepared using an electrospinning process, in which asol-gel was spun onto a collector drum to form a non-woven mat offibers. The sol-gel was made in two parts. First, TEOS was mixed withethanol, and then a second mixture containing HCl, water, and ethanolwas titrated into the mixture. The sol-gel was then allowed to ripen fora few days under controlled conditions before spinning.

In one example, the first sol was made by weighing out 384 grams of TEOS98% and 41.8 grams of anhydrous denatured ethanol, and pouring together.The first sol was allowed to let stand in a beaker, and a magneticstirrer was used to create a homogenous solution. The second sol wasmade by weighing 41.8 grams of anhydrous denatured ethanol, 16.4 gramsof distilled water, and 0.34 grams of hydrochloric acid, which was thenpoured together and mixed for 8 seconds with a magnetic stirrer until ahomogenous second sol was formed.

The second sol was then poured into the titration device, which wasplaced above a beaker containing the first sol. The titration devicethen dripped about 5 drops per second until a third sol was formed viathe mixing of the first sol and the second sol. During the drippingprocess, the first sol was continuously mixed with a magnetic stirrerwhile the second sol was dripped into the first sol.

The combined third sol was then placed into an enclosure box. A lowpressure vacuum was provided by a fan on medium speed to remove fumes.The air temperature within the box was 72° F. with 60% humidity. Thethird sol was allowed to sit and process for about three days. Themixtures were agitated daily to reduce the build-up of crystallinestructures. The third sol began to transition to sol-gel withevaporation of the alcohol solvent. Sol-gel may be monitored todetermine an approximate amount of C₂H₄ (ethylene) in the vapors, whichmay be in the range of about 10-20% relative to that of the original solbefore ripening. Upon proper gelatinization, the sol-gel was loaded intoelectrospinning machine or was frozen to preserve for electrospinning.In this example, proper gelatinization occurred when the total mass ofthe sol-gel was between about 70 grams and about 140 grams. This examplemay be scaled appropriately and the ranges may vary, yet still producedesirable structures. To further identify the ideal time to electropsin,portions of the gel may be dripped into the electric field of thespinning apparatus to evaluate the spinning properties of the sol-gel.

FIGS. 1A-1D are scanning electron microscopy (SEM) images of fibers spunin accordance with embodiments of the invention (50, 100, 200, and 500micron scales shown). As shown, the fibers are flexible, smooth, dense,and continuous (not significantly fractured). FIG. 2 is an SEM image offibers that were electrospun at a non-optimal time (before the sol-gelwas fully ripened) (20 micron scale shown), where the fibers are clearlyrigid with many fractures clearly evident. FIG. 3 shows a fiber mat spunin accordance with embodiments of the invention. The flexibility andcontinuity of the fibers allows mats to be spun at a thickness of ¼ inchor more. The mat has a soft, flexible texture.

FIGS. 4A and 4B are images comparing a silica fiber mat that waselectrospun when the sol-gel was ripened in accordance with embodimentsof the invention (FIG. 4A), with a fiber mat that was spun too early,before the sol-gel was optimally ripened or ripened too fast (FIG. 4B).The material in FIG. 4A has a soft texture, is very flexible, and can bespun at a thickness that is easily processed into dust-like particles.The material in FIG. 4B is brittle, inflexible, and thin.

A silica fiber mat was fabricated and broken into fragments by rubbingthrough a series of screens of decreasing mesh size. The final screenwas a 200 mesh screen, resulting in fiber dust and/or fibrous fragmentshaving sizes of approximately 20 μm to approximately 200 μm. FIGS. 5Aand 5B show SEM images of the resulting fiber dust, with 100 μm scaleshown. The soft texture of the material remains evident in the dustform.

For incorporating into a topical composition, a silica fiber matprepared as described above was rubbed through a 100 mesh screen. Theresulting silica fiber dust was incorporated into different topicalcompositions including: petroleum jelly, bacitracin ointment, facialcream, hand cream, and acne cream.

Example 2: Treatment of Shingles

A paste was prepared with bacitracin ointment and silica fiber dust. Thepaste was applied to the skin of a middle-age woman experiencingshingles. The ointment relieved the pain associated with the shingles.Petroleum jelly-silica fiber composition was also applied to affectedareas with similar results.

An exemplary treatment of shingles is shown in FIGS. 6A and 6B. FIG. 6Ashows the initial shingles rash, and FIG. 6B shows the same rash afterabout 1.5 days, with the topical composition being applied. Pain wasalso substantially reduced. Typically, it takes several weeks for ashingles rash to resolve.

Example 3: Treatment of Age Spots

A silica fiber composition prepared with generic facial cream wasprepared as described. The composition was applied over the course of 10days to age spots on the face of an adult male. Over 10 days the spotswere substantially faded.

Example 4: Treatment of Scar Tissue

A silica fiber composition was prepared with generic hand cream. Thecomposition was used routinely by an adult woman with scarring anddermatitis marks on her hands. Over time, the scarring and dermatitismarks subsided.

Example 5: Treatment of Acne

A silica fiber composition was prepared with acne cream, and applied tothe face of a female with acne blemishes and acne scarring on her face.With routine application, the scars and blemishes subsided.

Example 6: Burn Treatment

A silica fiber composition was applied to the torso of a middle-agedmale having a first/second degree burn. With routine application, theburn was substantially healed in about 4 days (compare FIG. 7A with FIG.7B).

In another example, a middle-aged male suffered 2nd and 3rd degree burnsresulting from an explosion. The burns covered the right hand and muchof the right arm, extending from the fingers to above the elbow. Afterabout one week from the accident, treatment with the silica fibers wasinitiated. The subject was still experiencing a significant amount ofpain prior to treatment. Within minutes of application of the fibers tothe wound, the pain was reported to be substantially alleviated.Sensations of tightness were reported.

Once the fibers were removed by showering, the pain returned, thoughwere lessened. With further application of the fibers, the pain wasagain substantially alleviated. By the following day, silica matrixwould not simply wash from the wound by showering. For the next week,the burns were dressed with the fiber matrix 2 to 3 times per day. Byday 3, the skin had started to grow back. After a little over one week,the majority of the skin had grown back over the wound area.

Once the new skin was formed over the burned area, treatmenttransitioned to a lotion with the silica matrix. The lotion was appliedto the burned area two to four times daily as necessary. After a coupleweeks of using the lotion, there was no visible scaring from the burns.There is slight discoloration in the pigment of the skin, which fadesover time.

Example 7: Treatment of Ichthyosis

A lotion composition was applied to the skin of a female subject (about18 months of age) having harlequin Ichthyosis. It was observed that therate at which excess skin was being produced had slowed drastically. Iswas further observed that the subject's body was better hydrated, mostlikely because the skin production was slower, and the extremely highcaloric needs were drastically reduced.

The terms and expressions employed herein are used as terms andexpressions of description and not of limitation, and there is nointention, in the use of such terms and expressions, of excluding anyequivalents of the features shown and described or portions thereof. Inaddition, having described certain embodiments of the invention, it willbe apparent to those of ordinary skill in the art that other embodimentsincorporating the concepts disclosed herein may be used withoutdeparting from the spirit and scope of the invention. Accordingly, thedescribed embodiments are to be considered in all respects as onlyillustrative and not restrictive.

1.-40. (canceled)
 41. A topical composition comprising a silica fiberpowder or dust, and a topical carrier.
 42. The topical composition ofclaim 41, wherein the topical carrier is a lotion, ointment, balm,paste, cream, foam, soap, shampoo, conditioner, bath salt, or gel. 43.The topical composition of claim 41, wherein the topical carrier is alotion, ointment, balm, paste, cream, or gel.
 44. The topicalcomposition of claim 41, wherein the silica fiber powder or dustconsists essentially of SiO₂.
 45. The topical composition of claim 41,wherein the topical composition comprises a hydrophobic phase.
 46. Thetopical composition of claim 45, wherein the hydrophobic phase comprisesone or more of almond oil, castor oil, cacao butter, coconut oil, cornoil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, poppyseed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, teaseedoil, jojoba oil, mineral oils, silicone oils, fatty oils, liquidparaffin, beeswax, lanolin, white soft paraffin, yellow soft paraffin,petrolatum, triglycerides, cetyl alcohol, stearyl alcohol, isopropylmyristate, oleic acid, isopropyl palmitate, stearic acid, a sorbitanesters of a fatty acid, and a sorbitan ester of a fatty acid andethylene oxide.
 47. The topical composition of claim 41, wherein thetopical composition comprises an aqueous phase.
 48. The topicalcomposition of claim 47, wherein the aqueous phase comprises a solventcomprising one or more of water, polyethylene glycol, propylene glycol,glycerol, sorbitol, ethanol, and isopropyl alcohol.
 49. The topicalcomposition of claim 41, wherein the silica fiber powder or dust isincorporated into the composition at from about 5 mg/ml to about 500mg/ml.
 50. The topical composition of claim 41, wherein the silica fiberpowder or dust is incorporated into the composition at from about 5mg/ml to about 250 mg/ml.
 51. The topical composition of claim 41,wherein the silica fiber powder or dust is incorporated into thecomposition at from about 25 mg/ml to about 100 mg/ml.
 52. The topicalcomposition of claim 41, wherein the topical composition is prepared byelectrospinning a sol-gel into a silica fiber composition, processingthe silica fiber composition into powder or dust, and incorporating thepowder or dust with the topical carrier.
 53. The topical composition ofclaim 52, wherein the sol-gel is prepared with tetraethyl orthosilicate(TEOS).
 54. The topical composition of claim 41, wherein the fibers ofthe silica fiber powder or dust have a variable diameter of from about50 nm to about 5 μm.
 55. The topical composition of claim 54, whereinthe fibers have a variable diameter predominately in the range of about200 to about 2000 nm.
 56. The topical composition of claim 41, furthercomprising one or more pharmaceutical or antimicrobial agents.
 57. Thetopical composition of claim 56, further comprising at least one of anantibiotic, an antiseptic, an anti-inflammatory agent, animmunosuppressant, a pain reducing agent, an anti-fibrotic, or ananti-scarring agent.
 58. The topical composition of claim 41, furthercomprising an antibiotic selected from the group consisting ofcephalosporin antibiotics, tetracycline antibiotics, beta-lactams,carbapenem antibiotics, polymyxin B, neomycin, and bacitracin.
 59. Thetopical composition of claim 41, further comprising an antisepticselected from the group consisting of phenol, meta-cresol,methylparaben, and sodium benzoate.
 60. The topical composition of claim41, further comprising a steroidal anti-inflammatory agent selected fromthe group consisting of hydroxyltriamcinolone, alpha-methyldexamethasone, beta-methyl betamethasone, beclomethasone dipropionate,clobetasol valerate, desonide, desoxymethasone, dexamethasone,diflorasone diacetate, diflucortolone valerate, fluadrenolone,fluclorolone acetonide, flumethasone pivalate, fluosinolone acetonide,fluocinonide, flucortine butylester, fluocortolone, fluprednidene(fluprednylidene) acetate, flurandrenolone, halcinonide, triamcinoloneacetonide, cortisone, cortodoxone, flucetonide, fludrocortisone,difluorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel,amcinafide, betamethasone, chloroprednisone, clocortelone, clescinolone,dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone,fluperolone, fluprednisolone, hydrocortisone, paramethasone,prednisolone, methylprednisolone, prednisone, and budesonide.
 61. Thetopical composition of claim 41, further comprising a non-steroidalanti-inflammatory agent selected from the group consisting of salicylicacid, acetyl salicylic acid, methyl salicylate, glycol salicylate,salicylmides, benzyl-2,5-diacetoxybenzoic acid, ibuprofen, fulindac,naproxen, ketoprofen, etofenamate, phenylbutazone, and indomethacin. 62.The topical composition of claim 41, further comprising one or more ofcortisone, hydrocortisone, acetaminophen, or a cannabinoid.
 63. Thetopical composition of claim 41, further comprising a thickenercomprising one or more of acacia, an alginate, carageenan, chitosan,collagen, tragacanth, xantham, a cellulose, an acrylic acid, a colloidalsolid, a hydrogel, and a thermoreversible polymer.
 64. The topicalcomposition of claim 41, further comprising an emulsifier selected fromthe group consisting of polyol esters, glycerol esters, sorbitanderivatives, sorbitan monolaurate, sorbitan monooleate, sorbitanmonostearate, sorbitan monopalmitate, sorbitan sesquioleate, sorbitantrioleate, sorbitan tristearate, polyoxyethylene sorbitan esters,polyoxyethylene esters, stearate esters of PEG, laurate esters of PEG,oleate esters of PEG, and myristate esters of PEG.
 65. A method fortreating skin tissue in a mammalian subject, the method comprising,applying the topical composition of claim 41 to said skin tissue. 66.The method of claim 65, wherein the composition is applied to a skinlesion, scar, superficial wound or infection, burn, cut, scrape, rash,blister, bug bite, poison ivy or poison oak, or hives.
 67. The method ofclaim 65, wherein the subject has epidermolysis bullosa or ichthyosis.68. The method of claim 65, wherein the composition is applied to asunburn or to a first, second, and/or third degree burn.
 69. The methodof claim 65, wherein the composition is applied to skin affected byeczema, atopic dermatitis, psoriasis, acne, rosacea, pruritus, shingles,lupus, dermatitis herpetiformis, or dermatomyositis.
 70. The method ofclaim 65, wherein the topical composition is applied as a bathcomprising the silica fiber powder or dust.